Wave Life Sciences (WVE) Scheduled to Post Earnings on Wednesday

Wave Life Sciences (NASDAQ:WVE – Get Rating) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, March 22nd. Analysts expect Wave Life Sciences to post earnings of ($0.42) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Wave Life Sciences Stock Performance

Shares of NASDAQ:WVE opened at $4.18 on Wednesday. Wave Life Sciences has a 52-week low of $1.16 and a 52-week high of $7.12. The company has a market capitalization of $363.24 million, a P/E ratio of -1.84 and a beta of -0.86. The company has a 50-day simple moving average of $4.72 and a 200 day simple moving average of $4.46.

Insider Buying and Selling at Wave Life Sciences

In other news, CEO Paul Bolno sold 29,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $4.04, for a total transaction of $118,776.00. Following the transaction, the chief executive officer now directly owns 407,425 shares of the company’s stock, valued at $1,645,997. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Paul Bolno sold 29,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $4.04, for a total transaction of $118,776.00. Following the transaction, the chief executive officer now directly owns 407,425 shares of the company’s stock, valued at $1,645,997. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kyle Moran sold 9,729 shares of the firm’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $4.04, for a total transaction of $39,305.16. Following the transaction, the chief financial officer now directly owns 79,751 shares in the company, valued at $322,194.04. The disclosure for this sale can be found here. Insiders have sold a total of 49,378 shares of company stock valued at $199,385 in the last three months. 32.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in WVE. BlackRock Inc. increased its stake in Wave Life Sciences by 1.5% in the first quarter. BlackRock Inc. now owns 2,937,786 shares of the company’s stock valued at $5,876,000 after acquiring an additional 43,423 shares during the last quarter. Renaissance Technologies LLC boosted its position in Wave Life Sciences by 450.1% in the first quarter. Renaissance Technologies LLC now owns 205,194 shares of the company’s stock valued at $410,000 after buying an additional 167,894 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Wave Life Sciences by 274.8% in the first quarter. Goldman Sachs Group Inc. now owns 421,412 shares of the company’s stock valued at $843,000 after buying an additional 308,966 shares in the last quarter. Mirabella Financial Services LLP acquired a new stake in Wave Life Sciences in the first quarter valued at approximately $44,000. Finally, BNP Paribas Arbitrage SA boosted its position in Wave Life Sciences by 457.0% in the second quarter. BNP Paribas Arbitrage SA now owns 20,777 shares of the company’s stock valued at $68,000 after buying an additional 17,047 shares in the last quarter. 77.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, SVB Leerink raised their target price on shares of Wave Life Sciences from $2.00 to $7.00 and gave the company a “market perform” rating in a research note on Wednesday, December 14th.

About Wave Life Sciences

(Get Rating)

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.